Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

Publications

Fabi SG, Hill C, Witherspoon JN, Boone SL, West DP

Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.

Journal of drugs in dermatology : JDD. 2009;8(8):765-9

Jeng WJ, Kuo MC, Shih LY, Chu PH

Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.

International journal of hematology. 2008;87(5):542-544

Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

JAMA. 2006;296(21):2558-60

Rajkumar SV

Thalidomide therapy and deep venous thrombosis in multiple myeloma.

Mayo Clinic proceedings. 2005;80(12):1549-51

Steurer M, Sudmeier I, Stauder R, Gastl G

Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha.

British journal of haematology. 2003;121(1):101-3

Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.

Cancer. 2002;95(8):1629-36